<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Long-chain polyunsaturated fatty acids (LCPUFA) for preterm and term infants
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Long-chain polyunsaturated fatty acids (LCPUFA) for preterm and term infants
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Long-chain polyunsaturated fatty acids (LCPUFA) for preterm and term infants
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven A Abrams, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard Martin, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 22, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1325468725">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supplementation of enteral feedings with long-chain polyunsaturated fatty acids (LCPUFAs) has been proposed to improve outcomes in infants, particularly neurodevelopmental outcomes. Accumulating evidence suggests that supplementing feedings with dietary LCPUFAs is beneficial for preterm infants. It remains uncertain whether supplements have benefits for term infants.
        </p>
        <p>
         This topic will review the evidence regarding whether or not dietary LCPUFA supplementation of enteral feedings is beneficial. The risk and benefits of maternal intake of LCPUFAs through fish intake during pregnancy and the potential benefits of LCPUFAs consumed as dietary seafood or fish oil in adults are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/431.html" rel="external">
          "Fish consumption and marine omega-3 fatty acid supplementation in pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5365.html" rel="external">
          "Fish oil: Physiologic effects and administration"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H109751441">
         <span class="h1">
          BACKGROUND
         </span>
        </p>
        <p class="headingAnchor" id="H174264629">
         <span class="h2">
          Metabolism and function
         </span>
         <span class="headingEndMark">
          —
         </span>
         LCPUFAs are configured as n-6 and n-3 structures (also referred to as omega-6 and omega-3 fatty acids, respectively). In an n-6 fatty acid, the first double bond from the methyl end is at the C6 position [
         <a href="#rid1">
          1
         </a>
         ]. In an n-3 fatty acid, the first double bond is at the C3 position [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The LCPUFAs are synthesized in the liver endoplasmic reticulum and peroxisomes by a series of desaturase and elongase enzymes, and the n-6 and n-3 LCPUFAs compete for these enzymes in their biosynthesis  (
         <a class="graphic graphic_figure graphicRef87057" href="/z/d/graphic/87057.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid3">
          3,4
         </a>
         ]. Biosynthesis depends on precursor availability and enzyme activity, which may be limiting in ill or preterm newborns [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3741497262">
         <span class="h3">
          Docosahexaenoic acid and other n-3 LCPUFAs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Docosahexaenoic acid (DHA) is the biologically active end product of alpha-linolenic acid, which is an essential fatty acid because it is exclusively attained from the diet. DHA is primarily derived from fish, especially oily fish such as herring, tuna, and salmon, as well as n-3-fed chickens and their eggs [
         <a href="#rid7">
          7
         </a>
         ]. Eicosapentaenoic acid is a precursor of DHA and is metabolized to DHA in the liver.
        </p>
        <p>
         DHA is important for development of the nervous system because it is an integral component of the phospholipid membrane of brain and retinal cells. DHA and eicosapentaenoic acid also play a role in antiinflammatory eicosanoid/docosanoid synthesis, signaling events, gene expression, and cytokine expression. In one study, DHA supplements to lactating mothers decreased inflammatory markers and increased relative DHA concentrations in their preterm infants [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         DHA is preferentially incorporated into the rapidly developing brain and retina during the last trimester of pregnancy and the first 24 months of life, with ongoing accumulation throughout childhood [
         <a href="#rid9">
          9-12
         </a>
         ]. Autopsy analysis estimates that the fetus accumulates 50 to 60 mg/day of DHA during the third trimester of gestation [
         <a href="#rid5">
          5
         </a>
         ]. It is estimated that the store of DHA at term birth is approximately 1050 mg [
         <a href="#rid13">
          13
         </a>
         ]. Over the first six months of life, infants accumulate DHA at a rate of approximately 20 mg/day and approximately one-half of all dietary DHA is incorporated into the brain. As a result, women who are pregnant or breastfeeding need to consume sufficient n-3 LCPUFA to ensure adequate DHA accretion in the fetus and breast milk.
        </p>
        <p class="headingAnchor" id="H1454289882">
         <span class="h3">
          Arachidonic acid and other n-6 LCPUFAs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Arachidonic acid (ARA) is the biologically active end product of alpha-linoleic acid, which is an essential fatty acid because it is exclusively attained from the diet. ARA can be derived directly from animal foods or seed oils, which are rich in n-6 linoleic acid, the precursor for ARA. In the United States, the typical diet is high in seed oils and thus higher in n-6 compared with n-3 LCPUFA. Human milk generally contains more ARA than DHA, and the amount does not vary substantially with maternal dietary intake [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         ARA is a major component of brain phosphoglycerides, generally in greater concentrations compared with DHA [
         <a href="#rid15">
          15
         </a>
         ]. In addition, ARA has a proinflammatory role in eicosanoid/docosanoid synthesis. Thus, the relative excess of n-6 LCPUFAs in the typical diet in the United States has a proinflammatory influence.
        </p>
        <p class="headingAnchor" id="H174264247">
         <span class="h2">
          Suggested dietary requirements
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following are published suggested enteral intakes in infants, representing expert consensus based primarily on indirect evidence from intrauterine accretion rates in healthy fetuses:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infants 0 to 6 months
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Institute of Medicine in the United States [
         <a href="#rid16">
          16
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         n-6 fatty acids 4.4 g/day
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         n-3 fatty acids 0.5 g/day
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         World Health Organization (WHO) [
         <a href="#rid17">
          17
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         ARA 0.4 to 0.6 percent of fatty acids
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         DHA 0.2 to 0.36 percent of fatty acids
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infants 6 to 24 months
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         WHO [
         <a href="#rid17">
          17
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Linoleic acid 3 to 4.5 percent of energy
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         DHA 10 to 12 mg/kg body weight
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preterm infants
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) [
         <a href="#rid18">
          18
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         DHA 12 to 30 mg/kg
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         ARA 18 to 42 mg/kg
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Alpha-linolenic acid (precursor for DHA) &gt;55 mg/kg
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Linoleic acid (precursor for ARA) 385 to 1540 mg/kg
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These ESPGHAN recommendations focus on infants weighing 1000 through 1800 g because this is the weight range in which most data are available [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H174264660">
         <span class="h2">
          LCPUFA content in milk
         </span>
        </p>
        <p class="headingAnchor" id="H174264684">
         <span class="h3">
          Human milk
         </span>
         <span class="headingEndMark">
          —
         </span>
         LCPUFA content varies in human milk and depends on maternal diet and body stores [
         <a href="#rid10">
          10,19,20
         </a>
         ]. Typical DHA concentration is 0.2 to 0.4 percent of total fatty acids (g per 100 g total fatty acids) but can be as low as 0.1 percent in the milk produced by a malnourished woman or as high as 2 percent in a woman who consumes fish as a main dietary source (a 20-fold increase) [
         <a href="#rid21">
          21,22
         </a>
         ].
        </p>
        <p>
         In the United States, the average amount of DHA in human milk is approximately 0.35 weight percent; a mother who consumes 100 mg/day of DHA will maintain this concentration in her breast milk [
         <a href="#rid23">
          23
         </a>
         ]. Term infants who consume 750 mL/day of human milk with a concentration of 0.35 weight percent have a daily DHA intake of 100 mg, which is consistent with the recommended intake outlined above. (See
         <a class="local">
          'Suggested dietary requirements'
         </a>
         above.)
        </p>
        <p>
         Human milk sources with low DHA concentration are more concerning for preterm infants who are deprived of fetal DHA that normally accrues at an average rate of 50 to 60 mg/kg/day during the last trimester of pregnancy [
         <a href="#rid9">
          9,24
         </a>
         ]. In the United States, DHA concentrations in maternal and donor human milk used in neonatal intensive care units are frequently low, with reported mean values between 0.1 and 0.32 weight percent, which may not meet the needs of premature infants [
         <a href="#rid19">
          19,21,25,26
         </a>
         ]. As an example, a DHA milk concentration of 0.1 weight percent only provides a dietary intake of 12 mg/kg/day for the preterm infant fed 150 mL/kg enteral milk, whereas a milk concentration of 0.5 weight percent at the same volume would result in an intake of 60 mg/kg/day [
         <a href="#rid4">
          4,27,28
         </a>
         ]. Thus, for some populations, human milk may be relatively low in DHA. In human milk-fed very low birth weight (VLBW) infants, enteral supplementation increases blood DHA concentrations and prevents the postnatal decline in levels that is seen without supplementation [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         The concentration of DHA in breast milk rises with increased maternal fish consumption [
         <a href="#rid30">
          30
         </a>
         ]. The United States Dietary Guidelines for Americans recommends consuming a variety of seafood to achieve at least 250 mg/week n-3 LCPUFA intake. Mercury in seafood is a concern primarily for fish harvested from contaminated waters. As a result, we follow the United States Environmental Protection Agency guidelines that recommend that breastfeeding mothers consume one to three weekly servings of a variety of types of seafood to ensure adequate breast milk DHA content [
         <a href="#rid31">
          31
         </a>
         ]. These recommendations are intended to achieve a maternal dietary DHA intake of at least 200 to 300 mg/day. (See
         <a class="medical medical_review" href="/z/d/html/431.html" rel="external">
          "Fish consumption and marine omega-3 fatty acid supplementation in pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H174264691">
         <span class="h3">
          Infant formula
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the 1980s and early 1990s, several studies demonstrated that n-3 LCPUFA concentration was lower in plasma and red blood cells of formula-fed infants compared with infants who received human milk [
         <a href="#rid32">
          32-34
         </a>
         ]. Data were also being accumulated on DHA's role in brain and retinal cell structural development [
         <a href="#rid9">
          9-12
         </a>
         ]. As a result, LCPUFAs, after obtaining the US Food and Drug Administration "GRAS" (Generally Recognized As Safe) status, were added in varying formulations and concentration to formulas for term and preterm infants. The vast majority of infant formula sold in the United States contains LCPUFAs, although the concentration varies between formulas, based on the manufacturer's decisions about targets for DHA intake. DHA-containing infant formulas generally provide DHA at concentrations of 0.15 to 0.32 weight percent (ie, percent of total fatty acids). This is intended to provide approximately the amount of DHA found in breast milk [
         <a href="#rid35">
          35
         </a>
         ]. However, whether LCPUFA (or DHA) supplementation has clinical benefits remains controversial, with the strongest evidence related to visual benefits. (See
         <a class="local">
          'Clinical trials'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1356262">
         <span class="h1">
          RATIONALE FOR LCPUFA SUPPLEMENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is some, but inconsistent, evidence that breastfeeding compared with infant formula feeding is associated with improved cognition (ie, 3 to 5 points on cognitive tests) and with visual acuity in preterm infants. Although the mechanism of this effect is uncertain, it has been hypothesized that these results are due, at least in part, to differences in docosahexaenoic acid (DHA) content, which is present in human milk but not in bovine milk. (See
         <a class="medical medical_review" href="/z/d/html/5013.html" rel="external">
          "Infant benefits of breastfeeding", section on 'Neurodevelopmental outcomes'
         </a>
         .)
        </p>
        <p>
         LCPUFAs, and particularly DHA, are important components of the developing brain and retina, accumulating especially during the third trimester of gestation and the first six months of life. Breastfed infants have higher levels of LCPUFA in the cerebral cortex than those fed standard infant formula [
         <a href="#rid36">
          36
         </a>
         ]. In addition, the known antiinflammatory effects of omega-3 (n-3) LCPUFAs have led to hypotheses that DHA supplementation to premature infants might reduce risks for comorbid disease.
        </p>
        <p>
         Together, these observations have led to the hypothesis that supplementation of bovine milk-based formula with LCPUFAs would improve cognition and visual acuity and possibly reduce comorbid disease in preterm infants. Addition of DHA to human milk via human milk fortifiers (HMFs) or supplements given to the lactating mother have also been suggested for preterm infants to compensate for the loss of accretion during the third trimester of pregnancy. However, clinical trials have not consistently shown that LCPUFA supplementation improves outcomes in preterm and term infants, as discussed below (see
         <a class="local">
          'Clinical trials'
         </a>
         below). Nonetheless, the overwhelming majority of infant formulas used in the United States and many other countries contain LCPUFA supplementation at varying levels.
        </p>
        <p class="headingAnchor" id="H7495424">
         <span class="h1">
          CLINICAL TRIALS
         </span>
         <span class="headingEndMark">
          —
         </span>
         More than 30 clinical trials have been conducted to evaluate the effect of supplementation of LCPUFAs. Most of the trials have focused on possible effects on cognition, visual acuity, and/or growth. The duration of omega-3 (n-3) LCPUFA feeding in infancy is consistently related to visual acuity at one year of age. Brain development as measured by the Bayley Scales of Infant and Toddler Development is not affected by LCPUFA feeding, though a few studies with specialized measures of problem-solving have been positive.
        </p>
        <p class="headingAnchor" id="H1232874163">
         <span class="h2">
          Term or preterm infants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies that analyzed the following outcomes focused on infants born at term or preterm. The study populations varied, but, when preterm infants were included, they were generally &gt;1500 g birth weight:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Visual acuity
         </strong>
         – Systematic reviews in preterm or term infants generally suggest that supplementation of infant formula with docosahexaenoic acid (DHA) has beneficial effects on visual acuity [
         <a href="#rid14">
          14,37-39
         </a>
         ]. As an example, a systematic review noted modest effects of LCPUFA supplementation in infant formula on visual acuity (as measured by visual evoked potentials) at 2, 4, and 12 months of age [
         <a href="#rid40">
          40
         </a>
         ]. The effect was small, with weighted mean difference -0.11 (95% CI -0.02 to -0.03).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cognitive outcomes
         </strong>
         – Four systematic reviews failed to show any significant effect of LCPUFA supplementation in infant formula on cognitive development, which was, in most cases, measured by the Bayley Scales of Infant and Toddler Development [
         <a href="#rid37">
          37,39,41,42
         </a>
         ]. One of these focused on preterm infants and found no significant effect on cognition as measured at 12 or 18 months post-term across seven studies [
         <a href="#rid37">
          37
         </a>
         ]. Another included a meta-analysis of 12 trials including 1802 term or preterm infants and also found no significant effect of LCPUFA overall or of LCPUFA dose or prematurity [
         <a href="#rid41">
          41
         </a>
         ]. Some studies compared different doses of LCPUFA in formula-fed infants, whereas others compared infants fed LCPUFA-supplemented formula with a human milk-fed control group. More data are needed to fully understand cognitive outcomes in supplemented human milk-fed preterm and full-term infants.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Very long-term data related to infant supplementation have begun to become available. In follow-up data from one study, infants who received LCPUFA-supplemented infant formula had long-term positive effects on brain structure, function, and neurochemical outcomes at 5.5 and 9 years of age compared with a control group fed a standard infant formula [
         <a href="#rid43">
          43,44
         </a>
         ]. Of note, some of these effects of DHA and arachidonic acid (ARA) may be mediated by genetic polymorphisms regulating fatty acid metabolism [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Growth
         </strong>
         – Although individual studies have reported either increased or decreased growth in infants with LCPUFA supplementation, meta-analyses showed no significant effect on growth overall [
         <a href="#rid37">
          37-39
         </a>
         ]. Nonetheless, preliminary data have shown a relationship between red blood cell n-3 LCPUFA concentrations and neonatal body composition, such that higher red blood cell DHA levels were associated with lower fat mass [
         <a href="#rid46">
          46
         </a>
         ]. Further studies are needed to determine relationships between LCPUFA levels and long-term body composition outcomes.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1232874170">
         <span class="h2">
          Very low birth weight infants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Effects of LCPUFA supplementation have been examined separately in very low birth weight (VLBW) infants (&lt;1500 g) because of the known deficiencies of LCPUFA in this population and their vulnerability to unique medical complications. The available clinical trial data on LCPUFA supplementation in VLBW infants are limited by considerable variability in study design, including differences in gestational ages and birth weights of the study participants, variability in the composition and dosing of supplements, differences in whether infants were fed human milk or formula, and variability in outcomes assessed.
        </p>
        <p>
         Taken together, the data suggest that DHA supplementation (whether provided through a human milk fortifier [HMF], infant formula, standalone supplement, or maternal supplementation) is safe and may improve outcomes for retinopathy of prematurity (ROP), vision, cognition, and, possibly, necrotizing enterocolitis (NEC). It is uncertain whether DHA increases the risk of bronchopulmonary dysplasia (BPD); if there is an effect, it is likely small and would not outweigh the other possible benefits in most circumstances. Most trials used DHA doses that approximate in utero accretion (eg, 50 to 80 mg/kg/day), which is more than that provided in human milk fortified with standard HMFs available in the United States (which provide approximately 20 mg/kg/day). The role for concomitant supplementation with ARA is unclear, although it is generally recommended that ARA be included when DHA is provided [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         The main evidence for each outcome is summarized below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ROP
         </strong>
         – In a randomized trial in infants &lt;28 weeks gestation, combined supplements with ARA (100 mg/kg/day) and DHA (50 mg/kg/day) decreased the risk of ROP by 50 percent (15.8 versus 33.3 percent; relative risk [RR] 0.50, 95% CI 0.28-0.91) [
         <a href="#rid47">
          47
         </a>
         ]. This beneficial effect occurred despite only modest increases in the serum levels of ARA and DHA. This study found no effect on other comorbid diseases, including NEC. By contrast, other trials and a meta-analysis did not detect a reduction in ROP rates in infants who received DHA supplementation [
         <a href="#rid48">
          48-50
         </a>
         ]. Many of these trials did not include ARA supplementation, and this may have contributed to lack of benefit. (See
         <a class="medical medical_review" href="/z/d/html/111238.html" rel="external">
          "Retinopathy of prematurity (ROP): Treatment and prognosis", section on 'Prevention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cognitive outcomes
         </strong>
         – The benefit of LCPUFA supplementation on cognitive outcomes in VLBW infants is supported by several randomized trials [
         <a href="#rid38">
          38,51-57
         </a>
         ]. Some studies have demonstrated improvements in mental development index (MDI) [
         <a href="#rid51">
          51,54,55
         </a>
         ], while others did not detect a difference [
         <a href="#rid56">
          56-58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4967.html" rel="external">
          "Long-term neurodevelopmental impairment in infants born preterm: Epidemiology and risk factors", section on 'Differences in study design'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a 2016 meta-analysis of seven randomized trials involving preterm infants, supplementation with any n-3 LCPUFA modestly improved cognitive scores at 18 to 24 months (mean difference 2.2 points [95% CI 0.05-4.4] on the Bayley-II MDI) [
         <a href="#rid38">
          38
         </a>
         ]. However, there was considerable heterogeneity between the trials in the meta-analysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The largest trial included in the meta-analysis was the DINO trial (
         <strong>
          D
         </strong>
         HA for the
         <strong>
          I
         </strong>
         mprovement of
         <strong>
          N
         </strong>
         eurodevelopmental
         <strong>
          O
         </strong>
         utcome in preterm infants), in which 657 preterm infants (&lt;33 weeks gestation, 45 percent &lt;1200 g) were randomly assigned to high-DHA or standard-DHA enteral feeds (primarily achieved through supplements given to lactating mothers) [
         <a href="#rid51">
          51
         </a>
         ]. At 18 months corrected age, the rate of severe developmental delay (defined as MDI &lt;70) was lower in the high-DHA group compared with the standard-DHA group (5.2 versus 10.5 percent, respectively; adjusted relative risk [aRR] 0.49, 95% CI 0.26-0.97). Mean MDI scores were not statistically different between the two groups (adjusted mean difference 1.6 points [95% CI -1.2 to 4.3]). In a follow-up study that included a subset of approximately 20 percent (n = 128) of the original DINO cohort, scores on standardized language and behavioral assessments at age two to five years were similar in both groups [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Further support for the benefit of DHA supplementation on cognitive outcomes in preterm infants is provided from a study published after the meta-analysis, which reported long-term neurodevelopmental outcomes in a subset of infants who were enrolled in one of the neonatal DHA supplementation trials described above [
         <a href="#rid48">
          48,54
         </a>
         ]. The original trial involved 1273 preterm infants (&lt;29 weeks gestation) who were randomly assigned to DHA supplementation (60 mg/kg/day) or placebo (soy emulsion) started at the time of initiating enteral feeds and continued until 36 weeks of postmenstrual age or neonatal intensive care unit discharge [
         <a href="#rid48">
          48
         </a>
         ]. Approximately 70 percent of the surviving children from the original trial cohort (n = 457) underwent cognitive assessment at age five years. Scores on standardized tests were higher for the DHA-supplemented group compared with placebo (adjusted mean difference 3.5 points [95% CI 0.4-6.5] for full-scale intelligence quotient [IQ]) [
         <a href="#rid54">
          54
         </a>
         ]. This difference approaches the four-point IQ difference that has been considered clinically relevant for public policy. The rate of severe cognitive impairment (IQ &lt;70) was lower in the DHA group compared with the control group (7 versus 12 percent), but the finding did not achieve statistical significance (aRR 0.6, 95% CI 0.33-1.08).
        </p>
        <p>
        </p>
        <p>
         The effects of maternal n-3 LCPUFA consumption during pregnancy on neurodevelopment and other outcomes in the offspring are inconclusive, as discussed in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/431.html" rel="external">
          "Fish consumption and marine omega-3 fatty acid supplementation in pregnancy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NEC
         </strong>
         – In a randomized trial in 226 VLBW infants, supplementation with DHA (75 mg/kg/day, without ARA, given during the first 14 days of enteral feeding) decreased the risk of NEC (RR 0.93, 95% CI 0.88-0.98) [
         <a href="#rid49">
          49
         </a>
         ]. In this study, most infants were fed formula rather than human milk. The study found no effect on other comorbid diseases, including ROP. By contrast, other trials and a meta-analysis did not detect a reduction in NEC rates in infants who received DHA supplementation [
         <a href="#rid47">
          47,50
         </a>
         ]. The observed effects on NEC incidence may be modulated by the amount of human milk in the diet as well as other factors such as probiotic use.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          BPD
         </strong>
         – In a meta-analysis of 14 trials (3531 preterm infants), rates of BPD were similar in infants who received DHA supplementation compared with control (28.4 versus 28.9 percent, respectively; RR 0.99, 95% CI 0.84-1.18) [
         <a href="#rid59">
          59
         </a>
         ]. In the largest trial, which involved more than 1200 infants &lt;29 weeks gestation, DHA supplementation (60 mg/kg/day without ARA supplementation) did not reduce the risk for BPD and, indeed, may have slightly increased this risk (RR 1.13, 95% CI 1.02-1.25) [
         <a href="#rid48">
          48
         </a>
         ]. Whether the lack of ARA supplementation in this study contributed to any adverse effect is uncertain. There was no significant effect on the incidence of other comorbidities, including ROP and NEC. The dose of supplemental DHA was intended to match the intrauterine accretion rate during the last trimester; enteral feeds supplied an additional 20 mg/kg/day DHA when full feeds were reached. Similarly, a large trial suggested that indirect supplementation (DHA given to lactating mothers) may have increased the infant's risk of BPD [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4104820185">
         <span class="h1">
          OUR APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on the above evidence, we suggest the following approach to LCPUFA nutrition for preterm and term infants:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maternal diet
         </strong>
         – Women who are pregnant or breastfeeding should include a source of omega-3 (n-3) LCPUFA in their diet, such as one to three weekly servings of seafood that is low in mercury  (
         <a class="graphic graphic_table graphicRef111607" href="/z/d/graphic/111607.html" rel="external">
          table 1
         </a>
         ), consistent with dietary guidelines in the United States [
         <a href="#rid31">
          31
         </a>
         ]. Women who are not able or willing to consume this amount and type of seafood should consume supplements or fortified foods to achieve docosahexaenoic acid (DHA) intake of at least 200 to 300 mg/day. This target is intended to provide sufficient amounts of n-3 LCPUFAs to ensure adequate accretion of n-3 LCPUFAs for the fetus and infant. This goal is particularly important for mothers of preterm infants because these infants miss the placental transfer of n-3 LCPUFAs during part of the third trimester. (See
         <a class="medical medical_review" href="/z/d/html/4960.html" rel="external">
          "Maternal nutrition during lactation", section on 'Fish intake'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/431.html" rel="external">
          "Fish consumption and marine omega-3 fatty acid supplementation in pregnancy"
         </a>
         and
         <a class="local">
          'Term or preterm infants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          DHA supplementation
         </strong>
         – For very low birth weight (VLBW) infants who are fed human milk, we suggest supplementation of DHA. DHA doses of 20 to 50 mg/day are supported by clinical evidence, but the optimal DHA dose and the role of concomitant supplementation with arachidonic acid (ARA) have not been established.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We achieve this supplementation using the combination of human milk with a standard human milk fortifier (HMF). The liquid HMFs available in the United States include DHA 15 to 20 mg/kg/day and ARA in approximately a 1:1.5 to 1:2 DHA:ARA (mg:mg) ratio [
         <a href="#rid61">
          61
         </a>
         ]. This is a safe and practical approach, although it supplies somewhat less DHA than was used in most clinical trials (50 to 80 mg/kg/day, with or without ARA), which found modest benefits of supplementation for some comorbidities of prematurity and for cognitive outcomes. In settings where the available HMFs do not contain DHA and ARA, it is reasonable to combine the available HMF with separate supplements to provide the target doses of DHA and ARA. (See
         <a class="local">
          'Very low birth weight infants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For formula-fed term and larger preterm infants (&gt;1500 g birth weight), data are mostly inconclusive regarding benefits of n-3 LCPUFA provision, although there may be some modest positive effects on visual outcomes. There is good evidence that addition of LCPUFAs to infant formula is safe and does not have adverse effects on growth using the typical doses in commercially available formulas [
         <a href="#rid23">
          23,37
         </a>
         ]. (See
         <a class="local">
          'Term or preterm infants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H341908781">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111345.html" rel="external">
          "Society guideline links: Breastfeeding and infant nutrition"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2011925730">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biochemistry and physiology
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Docosahexaenoic acid (DHA) is an omega-3 (n-3) long-chain polyunsaturated fatty acid (LCPUFA) that is the biologically active end product of the essential fatty acid, alpha-linolenic acid. It is an integral component of the brain and retinal phospholipid membrane. It is preferentially incorporated into the rapidly developing brain and retina during the last trimester of pregnancy and the first two years of life, with ongoing accumulation through childhood. (See
         <a class="local">
          'Docosahexaenoic acid and other n-3 LCPUFAs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         DHA is present in human milk but not in bovine milk. This is thought to be one possible mechanism for the beneficial effects of breastfeeding on neurocognitive and visual development compared with infant formula feeding. (See
         <a class="local">
          'Rationale for LCPUFA supplementation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5013.html" rel="external">
          "Infant benefits of breastfeeding", section on 'Neurodevelopmental outcomes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Arachidonic acid (ARA) is an omega-6 (n-6) LCPUFA that is the biologically active end product of alpha-linoleic acid. It is a major component of brain phosphoglycerides (generally in greater concentrations compared with DHA) and also has a proinflammatory role in eicosanoid/docosanoid synthesis. The ratio of ARA to DHA in the diet or supplements may influence the net effects on inflammation. (See
         <a class="local">
          'Arachidonic acid and other n-6 LCPUFAs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Preterm infants miss some of the fetal accretion of n-3 LCPUFAs including DHA and ARA, which normally occurs during the third trimester of pregnancy. Human milk often provides less DHA than needed to mimic the intrauterine accretion values of 50 mg/day. (See
         <a class="local">
          'Suggested dietary requirements'
         </a>
         above and
         <a class="local">
          'Human milk'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to LCPUFA supplementation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pregnant and lactating women
         </strong>
         – Pregnant and lactating women should consume one to three weekly servings of a variety of types of seafood high in n-3 LCPUFAs or consume another source of n-3 LCPUFAs that provides at least 200 mg/day DHA. This recommendation and the supporting evidence are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/431.html" rel="external">
          "Fish consumption and marine omega-3 fatty acid supplementation in pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Breast milk-fed infants
         </strong>
         – We encourage human milk feeding for virtually all infants for a variety of health benefits, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5013.html" rel="external">
          "Infant benefits of breastfeeding"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For most very low birth weight (VLBW) infants (&lt;1500 g) who are fed human milk, we suggest supplementation of DHA and ARA (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Until further information is available, it is reasonable to provide these nutrients through the combination of human milk plus a standard human milk fortifier (HMF) that contains DHA and ARA. The HMFs available in the United States provide approximately the target doses of DHA and ARA that are recommended by expert consensus in Europe. However, it should be noted that substantially higher doses were used for some of the clinical trials of LCPUFA supplementation in this population. (See
         <a class="local">
          'Our approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Clinical trials investigating DHA (with or without ARA supplementation) in VLBW infants have reached variable conclusions, with some finding lower rates of retinopathy of prematurity (ROP), modest improvements in cognitive outcomes, and reduced risk of necrotizing enterocolitis (NEC), while other trials did not detect a benefit in these outcomes. It is uncertain if DHA supplementation impacts the risk of bronchopulmonary dysplasia (BPD); on balance, the available evidence suggests minimal to no effect on BPD (neither benefit nor harm). (See
         <a class="local">
          'Very low birth weight infants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Formula-fed infants
         </strong>
         – For formula-fed term and preterm infants, we suggest using a formula that includes LCPUFAs (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). It is uncertain if including LCPUFAs in infant formula improves neurocognitive outcomes, but there may be some modest effects on visual outcomes and it appears to be safe. The vast majority of currently available infant formulas for term and preterm infants include LCPUFAs. Most provide DHA at concentrations of 0.15 to 0.32 weight percent (ie, percent of total fatty acids), which approximates the amount found in breast milk. However, the concentrations of DHA and ARA vary between formulas and the optimal concentrations remain uncertain. (See
         <a class="local">
          'LCPUFA content in milk'
         </a>
         above and
         <a class="local">
          'Term or preterm infants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H641872680">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Christina J Valentine, MD, MS, RD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Innis SM. Essential fatty acid transfer and fetal development. Placenta 2005; 26 Suppl A:S70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           The nomenclature of lipids (recommendations 1976). IUPAC-IUB Commission on Biochemical Nomenclature. J Lipid Res 1978; 19:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           German JB, Dillard CJ. Composition, structure and absorption of milk lipids: a source of energy, fat-soluble nutrients and bioactive molecules. Crit Rev Food Sci Nutr 2006; 46:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valentine CJ. Maternal dietary DHA supplementation to improve inflammatory outcomes in the preterm infant. Adv Nutr 2012; 3:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clandinin MT, Chappell JE, Heim T, et al. Fatty acid utilization in perinatal de novo synthesis of tissues. Early Hum Dev 1981; 5:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayes C, Burdge GC, Bingham A, et al. Variation in [U-13C] alpha linolenic acid absorption, beta-oxidation and conversion to docosahexaenoic acid in the pre-term infant fed a DHA-enriched formula. Pediatr Res 2006; 59:271.
          </a>
         </li>
         <li class="breakAll">
          Souci SW, Fachmann W, Kraut H. Food Composition and Nutrition Tables, 7th ed, MedPharm Scientific Publishers, Stuttgart, Germany 2008.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valentine CJ, Dingess KA, Kleiman J, et al. A Randomized Trial of Maternal Docosahexaenoic Acid Supplementation to Reduce Inflammation in Extremely Preterm Infants. J Pediatr Gastroenterol Nutr 2019; 69:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuipers RS, Luxwolda MF, Offringa PJ, et al. Fetal intrauterine whole body linoleic, arachidonic and docosahexaenoic acid contents and accretion rates. Prostaglandins Leukot Essent Fatty Acids 2012; 86:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Innis SM. Perinatal biochemistry and physiology of long-chain polyunsaturated fatty acids. J Pediatr 2003; 143:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez M. Tissue levels of polyunsaturated fatty acids during early human development. J Pediatr 1992; 120:S129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewin GA, Schachter HM, Yuen D, et al. Effects of omega-3 fatty acids on child and maternal health. Evid Rep Technol Assess (Summ) 2005; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cunnane SC, Francescutti V, Brenna JT, Crawford MA. Breast-fed infants achieve a higher rate of brain and whole body docosahexaenoate accumulation than formula-fed infants not consuming dietary docosahexaenoate. Lipids 2000; 35:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlson SE, Colombo J. Docosahexaenoic Acid and Arachidonic Acid Nutrition in Early Development. Adv Pediatr 2016; 63:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauritzen L, Brambilla P, Mazzocchi A, et al. DHA Effects in Brain Development and Function. Nutrients 2016; 8.
          </a>
         </li>
         <li class="breakAll">
          Institute of Medicine of the National Academies. Dietary Reference Intakes (DRIs): For Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids, The National Academies Press, Washington, DC 2005.
         </li>
         <li class="breakAll">
          Fats and fatty acids in human nutrition: Report of an expert consultation. Available at: foris.fao.org/preview/25553-0ece4cb94ac52f9a25af77ca5cfba7a8c.pdf (Accessed on October 23, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agostoni C, Buonocore G, Carnielli VP, et al. Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. J Pediatr Gastroenterol Nutr 2010; 50:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brenna JT, Varamini B, Jensen RG, et al. Docosahexaenoic and arachidonic acid concentrations in human breast milk worldwide. Am J Clin Nutr 2007; 85:1457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brenna JT. Animal studies of the functional consequences of suboptimal polyunsaturated fatty acid status during pregnancy, lactation and early post-natal life. Matern Child Nutr 2011; 7 Suppl 2:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen RG. Lipids in human milk. Lipids 1999; 34:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazzocchi A, D'Oria V, De Cosmi V, et al. The Role of Lipids in Human Milk and Infant Formulae. Nutrients 2018; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Innis SM. Omega-3 Fatty acids and neural development to 2 years of age: do we know enough for dietary recommendations? J Pediatr Gastroenterol Nutr 2009; 48 Suppl 1:S16.
          </a>
         </li>
         <li class="breakAll">
          Valentine CJ, Morrow G, Morrow AL. Promoting Pasteurized Donor Human Milk Use in the Neonatal Intensive Care Unit (NICU) as an adjunct to care and to Prevent Necrotizing Enterocolitis and shorten length of stay, F. a. D. A. Division of Dockets Management (HFA-305) (Ed), Rockville, MD 2010.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valentine CJ, Morrow G, Fernandez S, et al. Docosahexaenoic Acid and Amino Acid Contents in Pasteurized Donor Milk are Low for Preterm Infants. J Pediatr 2010; 157:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baack ML, Norris AW, Yao J, Colaizy T. Long-chain polyunsaturated fatty acid levels in US donor human milk: meeting the needs of premature infants? J Perinatol 2012; 32:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makrides M, Neumann MA, Gibson RA. Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition. Eur J Clin Nutr 1996; 50:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lapillonne A, Eleni dit Trolli S, Kermorvant-Duchemin E. Postnatal docosahexaenoic acid deficiency is an inevitable consequence of current recommendations and practice in preterm infants. Neonatology 2010; 98:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frost BL, Patel AL, Robinson DT, et al. Randomized Controlled Trial of Early Docosahexaenoic Acid and Arachidonic Acid Enteral Supplementation in Very Low Birth Weight Infants. J Pediatr 2021; 232:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quinn EA, Kuzawa CW. A dose-response relationship between fish consumption and human milk DHA content among Filipino women in Cebu City, Philippines. Acta Paediatr 2012; 101:e439.
          </a>
         </li>
         <li class="breakAll">
          U.S. Environmental Protection Agency: Advisories and technical resources for fish and shellfish consumption. Available at: https://www.epa.gov/fish-tech (Accessed on February 16, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ponder DL, Innis SM, Benson JD, Siegman JS. Docosahexaenoic acid status of term infants fed breast milk or infant formula containing soy oil or corn oil. Pediatr Res 1992; 32:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Putnam JC, Carlson SE, DeVoe PW, Barness LA. The effect of variations in dietary fatty acids on the fatty acid composition of erythrocyte phosphatidylcholine and phosphatidylethanolamine in human infants. Am J Clin Nutr 1982; 36:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makrides M, Neumann M, Simmer K, et al. Are long-chain polyunsaturated fatty acids essential nutrients in infancy? Lancet 1995; 345:1463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koletzko B, Bergmann K, Brenna JT, et al. Should formula for infants provide arachidonic acid along with DHA? A position paper of the European Academy of Paediatrics and the Child Health Foundation. Am J Clin Nutr 2020; 111:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farquharson J, Jamieson EC, Abbasi KA, et al. Effect of diet on the fatty acid composition of the major phospholipids of infant cerebral cortex. Arch Dis Child 1995; 72:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moon K, Rao SC, Schulzke SM, et al. Longchain polyunsaturated fatty acid supplementation in preterm infants. Cochrane Database Syst Rev 2016; 12:CD000375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newberry SJ, Chung M, Booth M, et al. Omega-3 Fatty Acids and Maternal and Child Health: An Updated Systematic Review. Evid Rep Technol Assess (Full Rep) 2016; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jasani B, Simmer K, Patole SK, Rao SC. Long chain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database Syst Rev 2017; 3:CD000376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qawasmi A, Landeros-Weisenberger A, Bloch MH. Meta-analysis of LCPUFA supplementation of infant formula and visual acuity. Pediatrics 2013; 131:e262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qawasmi A, Landeros-Weisenberger A, Leckman JF, Bloch MH. Meta-analysis of long-chain polyunsaturated fatty acid supplementation of formula and infant cognition. Pediatrics 2012; 129:1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beyerlein A, Hadders-Algra M, Kennedy K, et al. Infant formula supplementation with long-chain polyunsaturated fatty acids has no effect on Bayley developmental scores at 18 months of age--IPD meta-analysis of 4 large clinical trials. J Pediatr Gastroenterol Nutr 2010; 50:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lepping RJ, Honea RA, Martin LE, et al. Long-chain polyunsaturated fatty acid supplementation in the first year of life affects brain function, structure, and metabolism at age nine years. Dev Psychobiol 2019; 61:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liao K, McCandliss BD, Carlson SE, et al. Event-related potential differences in children supplemented with long-chain polyunsaturated fatty acids during infancy. Dev Sci 2017; 20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salas Lorenzo I, Chisaguano Tonato AM, de la Garza Puentes A, et al. The Effect of an Infant Formula Supplemented with AA and DHA on Fatty Acid Levels of Infants with Different FADS Genotypes: The COGNIS Study. Nutrients 2019; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farahnak Z, Yuan Y, Vanstone CA, Weiler HA. Maternal and neonatal red blood cell n-3 polyunsaturated fatty acids inversely associate with infant whole-body fat mass assessed by dual-energy X-ray absorptiometry. Appl Physiol Nutr Metab 2020; 45:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hellström A, Nilsson AK, Wackernagel D, et al. Effect of Enteral Lipid Supplement on Severe Retinopathy of Prematurity: A Randomized Clinical Trial. JAMA Pediatr 2021; 175:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins CT, Makrides M, McPhee AJ, et al. Docosahexaenoic Acid and Bronchopulmonary Dysplasia in Preterm Infants. N Engl J Med 2017; 376:1245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernabe-García M, Calder PC, Villegas-Silva R, et al. Efficacy of Docosahexaenoic Acid for the Prevention of Necrotizing Enterocolitis in Preterm Infants: A Randomized Clinical Trial. Nutrients 2021; 13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang P, Lavoie PM, Lacaze-Masmonteil T, et al. Omega-3 long-chain polyunsaturated fatty acids for extremely preterm infants: a systematic review. Pediatrics 2014; 134:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makrides M, Gibson RA, McPhee AJ, et al. Neurodevelopmental outcomes of preterm infants fed high-dose docosahexaenoic acid: a randomized controlled trial. JAMA 2009; 301:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henriksen C, Haugholt K, Lindgren M, et al. Improved cognitive development among preterm infants attributable to early supplementation of human milk with docosahexaenoic acid and arachidonic acid. Pediatrics 2008; 121:1137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isaacs EB, Ross S, Kennedy K, et al. 10-year cognition in preterms after random assignment to fatty acid supplementation in infancy. Pediatrics 2011; 128:e890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gould JF, Makrides M, Gibson RA, et al. Neonatal Docosahexaenoic Acid in Preterm Infants and Intelligence at 5 Years. N Engl J Med 2022; 387:1579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westerberg AC, Schei R, Henriksen C, et al. Attention among very low birth weight infants following early supplementation with docosahexaenoic and arachidonic acid. Acta Paediatr 2011; 100:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillot M, Synnes A, Pronovost E, et al. Maternal High-Dose DHA Supplementation and Neurodevelopment at 18-22 Months of Preterm Children. Pediatrics 2022; 150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almaas AN, Tamnes CK, Nakstad B, et al. Long-chain polyunsaturated fatty acids and cognition in VLBW infants at 8 years: an RCT. Pediatrics 2015; 135:972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smithers LG, Collins CT, Simmonds LA, et al. Feeding preterm infants milk with a higher dose of docosahexaenoic acid than that used in current practice does not influence language or behavior in early childhood: a follow-up study of a randomized controlled trial. Am J Clin Nutr 2010; 91:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Q, Zhou B, Cui Q, Chen C. Omega-3 Long-chain Polyunsaturated Fatty Acids for Bronchopulmonary Dysplasia: A Meta-analysis. Pediatrics 2019; 144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marc I, Piedboeuf B, Lacaze-Masmonteil T, et al. Effect of Maternal Docosahexaenoic Acid Supplementation on Bronchopulmonary Dysplasia-Free Survival in Breastfed Preterm Infants: A Randomized Clinical Trial. JAMA 2020; 324:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berseth CL, Harris CL, Wampler JL, et al. Liquid human milk fortifier significantly improves docosahexaenoic and arachidonic acid status in preterm infants. Prostaglandins Leukot Essent Fatty Acids 2014; 91:97.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 83231 Version 38.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15837071" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Essential fatty acid transfer and fetal development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/621435" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The nomenclature of lipids (recommendations 1976). IUPAC-IUB Commission on Biochemical Nomenclature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16403683" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Composition, structure and absorption of milk lipids: a source of energy, fat-soluble nutrients and bioactive molecules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22585914" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Maternal dietary DHA supplementation to improve inflammatory outcomes in the preterm infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7285840" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Fatty acid utilization in perinatal de novo synthesis of tissues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16439591" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Variation in [U-13C] alpha linolenic acid absorption, beta-oxidation and conversion to docosahexaenoic acid in the pre-term infant fed a DHA-enriched formula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16439591" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Variation in [U-13C] alpha linolenic acid absorption, beta-oxidation and conversion to docosahexaenoic acid in the pre-term infant fed a DHA-enriched formula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31058771" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A Randomized Trial of Maternal Docosahexaenoic Acid Supplementation to Reduce Inflammation in Extremely Preterm Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22115845" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Fetal intrauterine whole body linoleic, arachidonic and docosahexaenoic acid contents and accretion rates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14597908" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Perinatal biochemistry and physiology of long-chain polyunsaturated fatty acids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1532827" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Tissue levels of polyunsaturated fatty acids during early human development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16194124" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effects of omega-3 fatty acids on child and maternal health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10695931" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Breast-fed infants achieve a higher rate of brain and whole body docosahexaenoate accumulation than formula-fed infants not consuming dietary docosahexaenoate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27426911" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Docosahexaenoic Acid and Arachidonic Acid Nutrition in Early Development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26742060" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : DHA Effects in Brain Development and Function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26742060" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : DHA Effects in Brain Development and Function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26742060" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : DHA Effects in Brain Development and Function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19881390" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17556680" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Docosahexaenoic and arachidonic acid concentrations in human breast milk worldwide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21366867" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Animal studies of the functional consequences of suboptimal polyunsaturated fatty acid status during pregnancy, lactation and early post-natal life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10652985" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Lipids in human milk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29734711" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The Role of Lipids in Human Milk and Infant Formulae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19214053" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Omega-3 Fatty acids and neural development to 2 years of age: do we know enough for dietary recommendations?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19214053" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Omega-3 Fatty acids and neural development to 2 years of age: do we know enough for dietary recommendations?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20850762" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Docosahexaenoic Acid and Amino Acid Contents in Pasteurized Donor Milk are Low for Preterm Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22323096" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Long-chain polyunsaturated fatty acid levels in US donor human milk: meeting the needs of premature infants?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8793415" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21051909" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Postnatal docosahexaenoic acid deficiency is an inevitable consequence of current recommendations and practice in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33358843" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Randomized Controlled Trial of Early Docosahexaenoic Acid and Arachidonic Acid Enteral Supplementation in Very Low Birth Weight Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22759234" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A dose-response relationship between fish consumption and human milk DHA content among Filipino women in Cebu City, Philippines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22759234" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A dose-response relationship between fish consumption and human milk DHA content among Filipino women in Cebu City, Philippines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1287559" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Docosahexaenoic acid status of term infants fed breast milk or infant formula containing soy oil or corn oil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7091020" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The effect of variations in dietary fatty acids on the fatty acid composition of erythrocyte phosphatidylcholine and phosphatidylethanolamine in human infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7769900" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Are long-chain polyunsaturated fatty acids essential nutrients in infancy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31665201" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Should formula for infants provide arachidonic acid along with DHA? A position paper of the European Academy of Paediatrics and the Child Health Foundation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7741563" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Effect of diet on the fatty acid composition of the major phospholipids of infant cerebral cortex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27995607" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Longchain polyunsaturated fatty acid supplementation in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30307735" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Omega-3 Fatty Acids and Maternal and Child Health: An Updated Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28281303" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Long chain polyunsaturated fatty acid supplementation in infants born at term.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23248232" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Meta-analysis of LCPUFA supplementation of infant formula and visual acuity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22641753" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Meta-analysis of long-chain polyunsaturated fatty acid supplementation of formula and infant cognition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19881391" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Infant formula supplementation with long-chain polyunsaturated fatty acids has no effect on Bayley developmental scores at 18 months of age--IPD meta-analysis of 4 large clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30311214" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Long-chain polyunsaturated fatty acid supplementation in the first year of life affects brain function, structure, and metabolism at age nine years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27747986" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Event-related potential differences in children supplemented with long-chain polyunsaturated fatty acids during infancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30871048" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The Effect of an Infant Formula Supplemented with AA and DHA on Fatty Acid Levels of Infants with Different FADS Genotypes: The COGNIS Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31437414" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Maternal and neonatal red blood cell n-3 polyunsaturated fatty acids inversely associate with infant whole-body fat mass assessed by dual-energy X-ray absorptiometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33523106" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Effect of Enteral Lipid Supplement on Severe Retinopathy of Prematurity: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28355511" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Docosahexaenoic Acid and Bronchopulmonary Dysplasia in Preterm Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33671220" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Efficacy of Docosahexaenoic Acid for the Prevention of Necrotizing Enterocolitis in Preterm Infants: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24913791" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Omega-3 long-chain polyunsaturated fatty acids for extremely preterm infants: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19141765" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Neurodevelopmental outcomes of preterm infants fed high-dose docosahexaenoic acid: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18519483" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Improved cognitive development among preterm infants attributable to early supplementation of human milk with docosahexaenoic acid and arachidonic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21930549" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : 10-year cognition in preterms after random assignment to fatty acid supplementation in infancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36300974" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Neonatal Docosahexaenoic Acid in Preterm Infants and Intelligence at 5 Years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20624152" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Attention among very low birth weight infants following early supplementation with docosahexaenoic and arachidonic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35652296" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Maternal High-Dose DHA Supplementation and Neurodevelopment at 18-22 Months of Preterm Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25986018" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Long-chain polyunsaturated fatty acids and cognition in VLBW infants at 8 years: an RCT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20053878" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Feeding preterm infants milk with a higher dose of docosahexaenoic acid than that used in current practice does not influence language or behavior in early childhood: a follow-up study of a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31164440" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Omega-3 Long-chain Polyunsaturated Fatty Acids for Bronchopulmonary Dysplasia: A Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32662862" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Effect of Maternal Docosahexaenoic Acid Supplementation on Bronchopulmonary Dysplasia-Free Survival in Breastfed Preterm Infants: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24863250" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Liquid human milk fortifier significantly improves docosahexaenoic and arachidonic acid status in preterm infants.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
